WinstonWınston
Back
Stock

Insight Molecular Diagnostics

IMDX
26
Medical - Diagnostics & Research · Healthcare
Also trades as: 0KCC.L GBP 0.03 (-0.36%)
Price
$2.83
-0.01 (-0.35%)
Market Cap
$92.6M
Exchange
NASDAQ
Winston Score
26
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Oct 25, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
8/30
Growth
Mixed
7/20
Cash Flow
Weak
0/10
Stability
Weak
0/10
Valuation
Data not available
0/10
Ownership
Good
10/15
Dividends
Not counted
n/a

25 of 95 counted points = Winston Score 26. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+585.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 4.4M (2021) → 30.5M (2025)

§Winston Score History

The full picture

Insight Molecular Diagnostics Inc. is a small healthcare company that develops and sells molecular diagnostic tests. These tests help doctors detect diseases, infections, or genetic conditions by analyzing biological samples like blood or tissue. The company serves hospitals, clinics, and laboratories that need accurate diagnostic tools to guide patient treatment decisions.

The company earns revenue primarily by selling diagnostic test kits and related laboratory services to healthcare providers. It operates mainly in the United States, though it may pursue international markets over time. With a market cap of roughly $0.2 billion and a deeply negative operating margin, the company is spending far more than it earns, which is common for early-stage diagnostics firms still building out their product portfolio and customer base. The key risk is whether the company can scale revenue fast enough to reach profitability before it needs to raise additional capital, which could dilute existing shareholders.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-53.9% YoY

YoY Growth Rate

Revenue declining

Reported EPS Growth

-1.9% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.3042

30 Jun 2026: $-0.31

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS decreased year over year

R&D Spend

$16M/ year

↑ Rising (+62% vs prior year)

392.1% of revenue

21.8x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

68.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 months

$18M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Insight Molecular Diagnostics is putting 392% of revenue into R&D and that number is rising. That's 21.8x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
65.7%
Premium pricing power — 65.7% gross margin
Profit after running costs
Operating Margin
-4770.7%
Losing money on operations — -4770.7%
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-60.8%
Shrinking sales (-60.8% YoY)
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
—
Data not available
Spare cash per sale
FCF Margin
-1848.8%
Burning cash (-1848.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
3.07
Heavy debt load (3.07)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
—
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial